WCN26-4580 Telitacicept add glucocorticoids versus telitacicept alone in the treatment of IgA nephropathy: a real-world study

Read full text Summarise with VIRAT
Authors: Yan Yang, Yafei Chen, Xialian Xu, Shi Jin, Xiaoqiang Ding, Yiqin Shi, Shengzhuo You
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Telitacicept, a novel fusion protein that targets B lymphocyte stimulator and a proliferation-inducing ligand, has been used in autoimmune diseases. However, the efficacy and safety of telitacicept combined with glucocorticoids (GCs) in the treatment of immunoglobulin A nephropathy (IgAN) remain unclear.

Fields of Study & Subjects

Renal Diseases and Glomerulopathies Renal Transplantation Outcomes and Treatments Chronic Kidney Disease and Diabetes

Publication details

Journal / source
Kidney International Reports
Volume
11
Issue
4
Pages
106232–106232
Publication date
25 March 2026
Language
EN